<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868385</url>
  </required_header>
  <id_info>
    <org_study_id>RePST</org_study_id>
    <secondary_id>2016-003017-10</secondary_id>
    <nct_id>NCT02868385</nct_id>
  </id_info>
  <brief_title>Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)</brief_title>
  <acronym>RePST</acronym>
  <official_title>Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Suisse de Recherches Scientifiques en Cote d'Ivoire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, randomized controlled trial of single vs. multiple treatments of praziquantel&#xD;
      in intestinal African schistosomiasis in Côte d'Ivoire&#xD;
&#xD;
      This study aims to determine the efficacy of repeated (up to four times) praziquantel&#xD;
      treatment against S. mansoni infection in school-age children from Côte d'Ivoire using the&#xD;
      traditional Kato-Katz thick smear technique, but also with more accurate and non-invasive&#xD;
      antigen- and DNA-detection methods.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">January 14, 2019</completion_date>
  <primary_completion_date type="Actual">January 14, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>The difference in cure rate (percentage negative) between intervention and control arm by Kato-Katz technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction rates</measure>
    <time_frame>8 weeks</time_frame>
    <description>The difference in egg reduction rate (by Kato-Katz), cure rate and circulating anodic and cathodic antigen and DNA reduction rate after multiple doses of praziquantel (40 mg/kg) by Kato Katz (KK), point-of-care circulating cathodic antigen assay (POC-CCA), up-converting phosphor lateral flow circulating anodic antigen assay (UCP-LF-CAA) and polymerase chain reaction (PCR), respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Sensitivity and specificity of Kato Katz (KK), point-of-care circulating cathodic antigen assay (POC-CCA), up-converting phosphor lateral flow circulating anodic antigen assay (UCP-LF-CAA) and polymerase chain reaction (PCR) at different time points.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Schistosomiasis</condition>
  <arm_group>
    <arm_group_label>Control group (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4x praziquantel: Children assigned to group B receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive three consecutive praziquantel treatments (40 mg/kg) in the following six weeks with 2 weeks intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4x Praziquantel</intervention_name>
    <description>Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.</description>
    <arm_group_label>Intervention group (B)</arm_group_label>
    <other_name>Biltricide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1x Praziquantel</intervention_name>
    <description>One praziquantel treatment (40 mg/kg) at baseline</description>
    <arm_group_label>Control group (A)</arm_group_label>
    <other_name>Biltricide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a confirmed S. mansoni infection (positive POC-CCA test result and at&#xD;
             least one positive out of triplicate Kato-Katz thick smears)&#xD;
&#xD;
          -  Subject is aged between 5 and 18 years and otherwise in good health&#xD;
&#xD;
          -  Subject has received no recent praziquantel treatment in the past month&#xD;
&#xD;
          -  Subject has provided oral assent and provided written informed consent signed by&#xD;
             parents/legal guardian&#xD;
&#xD;
          -  Subject is able and willing to provide multiple stool and urine samples during study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to study medication (i.e. praziquantel and albendazole)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Coulibaly</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Suisse de Recherches Scientifiques en Cote d'Ivoire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Suisse de Recherches Scientifiques en Côte d'Ivoire</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <reference>
    <citation>Hoekstra PT, Casacuberta Partal M, Amoah AS, van Lieshout L, Corstjens PLAM, Tsonaka S, Assaré RK, Silué KD, Meité A, N'Goran EK, N'Gbesso YK, Roestenberg M, Knopp S, Utzinger J, Coulibaly JT, van Dam GJ. Repeated doses of Praziquantel in Schistosomiasis Treatment (RePST) - single versus multiple praziquantel treatments in school-aged children in Côte d'Ivoire: a study protocol for an open-label, randomised controlled trial. BMC Infect Dis. 2018 Dec 14;18(1):662. doi: 10.1186/s12879-018-3554-2.</citation>
    <PMID>30547750</PMID>
  </reference>
  <results_reference>
    <citation>Hoekstra PT, Casacuberta-Partal M, van Lieshout L, Corstjens PLAM, Tsonaka R, Assaré RK, Silué KD, Meité A, N'Goran EK, N'Gbesso YK, Amoah AS, Roestenberg M, Knopp S, Utzinger J, Coulibaly JT, van Dam GJ. Efficacy of single versus four repeated doses of praziquantel against Schistosoma mansoni infection in school-aged children from Côte d'Ivoire based on Kato-Katz and POC-CCA: An open-label, randomised controlled trial (RePST). PLoS Negl Trop Dis. 2020 Mar 20;14(3):e0008189. doi: 10.1371/journal.pntd.0008189. eCollection 2020 Mar.</citation>
    <PMID>32196506</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Meta Roestenberg</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Schistosomiasis</keyword>
  <keyword>Schistosoma mansoni</keyword>
  <keyword>Bilharzia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schistosomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

